R
Rainer Schwerdtfeger
Researcher at University of Antwerp
Publications - 144
Citations - 10244
Rainer Schwerdtfeger is an academic researcher from University of Antwerp. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 50, co-authored 143 publications receiving 9519 citations. Previous affiliations of Rainer Schwerdtfeger include Ludwig Maximilian University of Munich & University of Jena.
Papers
More filters
Journal ArticleDOI
Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia
Vanderson Rocha,Myriam Labopin,Guillermo Sanz,William Arcese,Rainer Schwerdtfeger,Alberto Bosi,Niels Jacobsen,Tapani Ruutu,Marcos de Lima,Jürgen Finke,Francesco Frassoni,Eliane Gluckman +11 more
TL;DR: Cord blood from an unrelated donor is an alternative source of hematopoietic stem cells for adults with acute leukemia who lack an HLA-matched bone marrow donor.
Journal ArticleDOI
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Jürgen Finke,Wolfgang Bethge,Claudia Schmoor,Hellmut Ottinger,Matthias Stelljes,Axel R. Zander,Liisa Volin,Tapani Ruutu,Dominik Heim,Rainer Schwerdtfeger,Karin Kolbe,Jiri Mayer,Johan Maertens,Werner Linkesch,Ernst Holler,Vladimir Koza,Martin Bornhäuser,Hermann Einsele,Hans-Jochem Kolb,Hartmut Bertz,Matthias Egger,Olga Grishina,Gérard Socié +22 more
TL;DR: The addition of ATG-F to GVHD prophylaxis with ciclosporin and methotrexate resulted in decreased incidence of acute and chronic GV HD without an increase in relapse or non-relapse mortality, and without compromising overall survival.
Journal ArticleDOI
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Christoph Schmid,Michael Schleuning,Rainer Schwerdtfeger,Bernd Hertenstein,Eva Mischak-Weissinger,Donald Bunjes,Stephanie von Harsdorf,Christoph Scheid,Udo Holtick,Hildegard Greinix,Felix Keil,Barbara Schneider,Michael Sandherr,Gesine Bug,Johanna Tischer,Georg Ledderose,Michael Hallek,Wolfgang Hiddemann,Hans-Jochem Kolb +18 more
TL;DR: A sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem cell transplantation (SCT), and prophylactic donor lymphocyte transfusion (pDLT) was studied in 103 patients with refractory acute myeloid leukemia, indicating a high activity of the regimen in refractor AML.
Journal ArticleDOI
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kröger,Ernst Holler,Guido Kobbe,Martin Bornhäuser,Rainer Schwerdtfeger,Herrad Baurmann,Arnon Nagler,Wolfgang Bethge,Matthias Stelljes,Lutz Uharek,Hannes Wandt,Andreas Burchert,Paolo Corradini,Jörg Schubert,Martin Kaufmann,Peter Dreger,Gerald Wulf,Hermann Einsele,Tatjana Zabelina,Hans Michael Kvasnicka,Jürgen Thiele,Ronald Brand,Axel R. Zander,Dietger Niederwieser,Theo de Witte +24 more
TL;DR: A prospective multicenter phase 2 trial to determine efficacy of a busulfan-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors found that age older than 55 years and human leukocyte antigen-mismatched donor remained significant factors for survival.
Journal ArticleDOI
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease
Daniel Wolff,Michael Schleuning,Stephanie von Harsdorf,Ulrike Bacher,Armin Gerbitz,Michael Stadler,Francis Ayuk,Alexander Kiani,Rainer Schwerdtfeger,Georgia B. Vogelsang,Guido Kobbe,Martin Gramatzki,Anita Lawitschka,Mohamad Mohty,Steven Z. Pavletic,Hildegard T. Greinix,Ernst Holler +16 more
TL;DR: The consensus conference on clinical practice in cGVHD held in Regensburg aimed to achieve a consensus on the current evidence of treatment options as well as to provide guidelines for daily clinical practice.